Adhd Treatment

Adult ADHD treatment is one of the parts of psychiatry where the gap between what works and what most patients actually get prescribed is genuinely wide. The medications are old. The data is good. And somehow a huge percentage of adults with ADHD are either on the wrong thing, on the right thing at the wrong dose, or still trying to white-knuckle through their week on coffee and shame. The field knows what works, the field also keeps not doing it, which honestly explains a lot about how prescribing patterns drift.

The mechanism worth knowing, in plain language: the front part of your brain that’s supposed to do the boring grown-up jobs (planning, paying attention to one thing for more than a minute, remembering what you walked into the room to do, not blurting things out, running your day) doesn’t hold onto its own dopamine and norepinephrine signals the way other brains do. The signal fades before the task finishes. That’s why you can write the email in your head at 2 AM and still not be able to type it on Tuesday. Stimulants put more of those neurotransmitters in the gap between brain cells and keep them there long enough for the front of your brain to actually run its program. That’s the whole mechanism, and everything else is detail.

The detail is where it goes sideways. Which stimulant, which release profile, what dose, what to do if you can’t take stimulants at all, when to add something else, how to handle the Schedule II controlled-substance paperwork now that telehealth rules keep moving. None of it is intuitive. A lot of prescribers who don’t see ADHD often just write 20mg of Adderall IR twice a day and hope, and that’s how you end up with a patient who tried two doses of one stimulant five years ago and is now convinced ADHD meds don’t work for them.

What the workup should look like, and why most providers skip it

The diagnosis is clinical. No blood test, no scan, no neuropsych battery that confirms it. What there should be is an actual conversation that goes back to childhood, because ADHD doesn’t start at 32. It started at 7 and got missed, or got managed by a parent who structured the kid’s life for him, or the kid was smart enough to coast until college handed him a syllabus with no scaffolding and the whole thing unraveled.

The eval that’s worth getting includes whether the symptoms were there since elementary school (report cards help), what’s been happening at home, what your dad was like (this is heritable as hell and often the diagnosis lands on the patient and the father quietly recognizes himself in the questions), and a real look at what else might be doing the same thing on the outside. Sleep apnea presenting as inattention is a regular miss, a couple times a year for any prescriber who’s paying attention. Untreated anxiety eats short-term recall in a way that looks identical to ADHD from the outside. Iron deficiency in women with heavy periods tanks attention. Thyroid is worth a check. So is whether you’re running on five hours of sleep and calling it normal.

The kind of guy who comes in convinced he has ADHD because he can’t get anything done at work, and whose ferritin (the iron storage protein the lab measures to see whether you’re iron-deficient even with a normal hemoglobin) is 11, doesn’t need a stimulant. He needs iron. Not the typical case, but it’s the reason you do the workup instead of skipping to the script, because the cost of skipping is putting somebody on a controlled substance for a problem the controlled substance isn’t going to fix.

The medication ladder, in the order that actually works

Stimulants are first-line for adult ADHD because they’re the most effective psychiatric medication we have for any condition, full stop. Response rates land around 70 to 80 percent if you actually titrate (which is the part most prescribers skip). The two families are methylphenidate (Ritalin, Concerta, Focalin) and amphetamine (Adderall, Vyvanse, Mydayis). They work on overlapping but not identical wiring, and the trick is that some people respond beautifully to one family and feel nothing on the other. There’s no test that predicts which way it goes. You try one, and if it doesn’t fit, you try the other.

Stimulants don’t build the systems. They make it possible to build the systems.

Conventional wisdom, including the residency textbooks, says methylphenidate is the “gentler” option and amphetamines are the “stronger” one. My take, against the textbook: in practice it’s often the opposite. More jitters, more dry mouth, more “something feels off” with methylphenidate than with amphetamines for a lot of adults. Patients steered toward methylphenidate as the “lighter” option frequently end up wanting to switch. Vyvanse 30mg as a starting place for most adults is a defensible default precisely because it’s smoother than Adderall XR and harder to misuse, and the response curve is cleaner.

If somebody has anxiety, cardiac stuff in the family, or just runs hot, methylphenidate as a starting place is reasonable because it tends to be less activating. Concerta 27mg or 36mg is the usual entry point there. But “less activating” isn’t the same as “the cautious choice for cautious patients,” it’s just a different drug profile.

The IR-versus-extended-release question matters more than most providers acknowledge. Immediate release peaks in an hour, wears off in four, and produces a rollercoaster that some people love (predictable, easy to plan around) and others hate (the crash feels like withdrawal). Extended release gives you eight to twelve hours of steadier coverage but you can’t fine-tune the timing, and if you start at 9 AM you may still be wired at 9 PM. A lot of adult patients end up on a long-acting in the morning with a short-acting booster in the early afternoon, which is a perfectly reasonable shape that a lot of prescribers don’t reach for because it’s two prescriptions instead of one.

Most “I tried ADHD meds and they didn’t help” stories are really “nobody titrated me correctly and I quit at week two.”

If stimulants are off the table because of cardiac issues, a real substance use history, or you’ve tried both families and they both made you feel like a stranger, the next option is atomoxetine (Strattera, the only non-stimulant in the SNRI family that’s FDA-approved for ADHD). It’s not scheduled. Takes four to six weeks to do anything. About half as effective as a stimulant in head-to-head studies, but real for the people it works for. Guanfacine ER (Intuniv, an old blood pressure drug that got a second life as an ADHD medication, particularly for the irritability-and-short-fuse piece) is the other non-stimulant, sometimes a monotherapy and more often an adjunct to a stimulant if the afternoon edge is too sharp. Bupropion (Wellbutrin) is off-label and worth a try if there’s depression in the mix, but it’s nobody’s first choice for ADHD alone.

The cardiac caveat that most providers won’t say plainly

Stimulants aren’t no-risk. The marketing keeps wanting them to be, and the productivity-and-focus discourse keeps wanting them to be, and they’re not. If you’ve got cardiac stuff in the family, an arrhythmia, untreated high blood pressure, or you’re already on a couple of heart medications, the first-time-stimulant conversation is genuinely fraught. Any prescriber who tells you stimulants are completely safe in cardiac patients is a damn liar, full stop. Anyone over 50 starting their first stimulant is a different risk conversation than a 30-year-old starting Vyvanse for the first time. Cardiac workup, EKG, talk to the cardiologist, monitor BP and pulse at every follow-up. If the prescriber isn’t doing that, find one who will.

Any prescriber who tells you stimulants are completely safe in cardiac patients is a damn liar, full stop.

That isn’t a reason to never prescribe in cardiac patients. It’s a reason to do the workup and monitor instead of pretending the issue isn’t there.

What the medication doesn’t do

Stimulants don’t build the systems. They make it possible to build the systems. If you take Vyvanse and then sit in the same chaos of unopened mail and 47 browser tabs, you’ll hyperfocus on something useless for nine hours and end the day worse off because now you can’t even blame your brain. Most of the adults who plateau on ADHD medication are sleeping badly and don’t want to talk about it. Eight hours, dark room, phone out of the bedroom, no caffeine after noon. The advice is boring, and it keeps working anyway.

Structure is the second piece. External structure, because the internal kind is what’s broken. Calendars you actually look at, a single notebook for the day, alarms for the transitions you keep missing, somebody who knows what you’re working on so you can’t quietly disappear. ADHD coaching is underrated for this. A real coach who’s worked with adults will do more for your week than another medication adjustment, and most prescribers don’t suggest it because they’re not coaches and they’re paid to write the prescription, not to send you to somebody who’s better at the rest.

The accommodations conversation matters too, and most adults skip it because they don’t want to be the ADHD person at work. You don’t have to disclose to use the tools. Noise-canceling headphones, written task lists instead of verbal handoffs, longer deadlines on the projects that need deep work. If you’re in school, formal accommodations through disability services are worth the paperwork. Extra time on exams levels a surface that was tilted the whole time.

The autonomy piece, because the field keeps getting this wrong from both sides

The field is wrong about ADHD medication in both directions at once, which is sort of the meta-problem with how this gets handled. There’s a generation of prescribers who treat stimulants as a casual lifestyle drug to be handed out after a fifteen-minute eval, and a different generation who treat them as a controlled substance to be gatekept until the patient proves they deserve it. Both of those positions are wrong, and which one your prescriber happens to fall into mostly determines what your treatment looks like.

The right framing is patient-autonomy. The patient who’s done a real eval, understands the risk profile (including the cardiac piece), and wants a stimulant trial gets one. The provider’s job is the honest take on what’s likely to work and what the trade-offs are. The patient’s job is the choice. The most a thoughtful prescriber should do, if they have personal reservations about a particular case, is a disapproving yes where you walk out with the script plus a clear sense of what they’d watch for. Hardly ever should the answer be no.

The flip side: anyone walking in expecting a Schedule II at the first telehealth visit with no records, no real history, and no PDMP check should be suspicious of the practice writing it for them, because the practice that does that is the practice whose DEA registration is going to get pulled, and then the patient is back to scrambling.

The telehealth and controlled-substance reality

Stimulants are Schedule II, which means the prescribing rules are stricter than for anything else in psychiatry. The DEA’s pandemic-era flexibilities for telehealth controlled substances have been extended several times and the rules keep moving. Most prescribers can still start a stimulant via telehealth in many situations, but a lot of clinics require at least one in-person visit before they’ll write a Schedule II, and some states layer their own rules on top. Don’t expect a stimulant prescription on the first telehealth visit with a new provider, especially without records.

Refills can’t be auto-sent within a 90-day window, pharmacies can’t transfer Schedule II scripts between locations, and if your usual pharmacy is out of Adderall (which happens, sometimes for weeks at a stretch), you’ll need a new written script sent to wherever has stock. None of this is fixable on your end, all of it is just the cost of doing business with Schedule II prescribing, and the prescriber who’s a pain in the ass about helping you navigate it is the prescriber you should leave.

What’s actually nice to hear, if you’re starting this process and feeling like the system is built to wear you down. Most adults who land on the right ADHD medication at the right dose stay on it for years, and most of them describe the same thing once it’s working. The fog they didn’t know they were in lifts. They sit at their desk and do the thing they intended to do, and then they stand up and do the next thing, and there isn’t a twenty-minute internal negotiation between them. That isn’t a transformation. It’s just the wiring finally cooperating. If the wiring’s been fighting you for two decades, it’s worth finding out whether that’s what’s been going on.

Sources

1. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. PMID 33549739.
2. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder. Lancet Psychiatry. 2018;5(9):727-738. PMID 30097390.
3. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. PMID 16585449.
4. Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2022;2(2):CD012857. PMID 35201607.